Search Results - "Gionata Fiorino"

A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies by Beeg, Marten, Nobili, Alessandro, Orsini, Barbara, Rogai, Francesca, Gilardi, Daniela, Fiorino, Gionata, Danese, Silvio, Salmona, Mario, Garattini, Silvio, Gobbi, Marco

“…Therapeutic drug and immunogenicity monitoring (TDIM) is increasingly proposed to guide therapy with biologics, characterised by high inter-individual…”
Get full text

Novel therapeutic targets for inflammatory bowel disease by Argollo, Marjorie, Fiorino, Gionata, Hindryckx, Pieter, Peyrin-Biroulet, Laurent, Danese, Silvio

“…Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions associated with progressive damage…”
Get full text

Biological Agents for Moderately to Severely Active Ulcerative Colitis by DANESE, Silvio, FIORINO, Gionata, PEYRIN-BIROULET, Laurent, LUCENTEFORTE, Ersilia, VIRGILI, Gianni, MOJA, Lorenzo, BONOVAS, Stefanos

Get full text

Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile by Danese, Silvio, Fiorino, Gionata

“…Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as for the originator. Some concerns about safety and…”
Get more information

The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges by Noviello, Daniele, Mager, Riccardo, Roda, Giulia, Borroni, Riccardo G., Fiorino, Gionata, Vetrano, Stefania

“…Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract, characterized by a dysregulated innate and adaptive immune response to gut…”
Get full text

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience by D’Amico, Ferdinando, Parigi, Tommaso Lorenzo, Fiorino, Gionata, Peyrin-Biroulet, Laurent, Danese, Silvio

“…Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently…”
Get full text

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update by Danese, Silvio, Fiorino, Gionata, Raine, Tim, Ferrante, Marc, Kemp, Karen, Kierkus, Jaroslaw, Lakatos, Peter L, Mantzaris, Gerassimos, van der Woude, Janneke, Panes, Julian, Peyrin-Biroulet, Laurent

Get full text

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study by Allocca, Mariangela, Fiorino, Gionata, Bonovas, Stefanos, Furfaro, Federica, Gilardi, Daniela, Argollo, Marjorie, Magnoni, Paola, Peyrin-Biroulet, Laurent, Danese, Silvio

“…Colonoscopy [CS] is the standard for assessing disease activity in ulcerative colitis [UC], although invasive and poorly tolerated. Bowel ultrasound [BUS] may…”
Get full text

Calcium supplementation for the prevention of colorectal adenomas: a systematic review and meta-analysis of randomized controlled trials by Bonovas, Stefanos, Fiorino, Gionata, Lytras, Theodore, Malesci, Alberto, Danese, Silvio

“…AIM: To determine the efficacy of calcium supplementation in reducing the recurrence of colorectal adenomas.METHODS: We conducted a systematic review and…”
Get full text

Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target by Allocca, Mariangela, Jovani, Manol, Fiorino, Gionata, Schreiber, Stefan, Danese, Silvio

“…Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn's disease (CD) and…”
Get more information

Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures by Fiorino, Gionata, Gilardi, Daniela, Radice, Simona, Furfaro, Federica, Allocca, Mariangela, Danese, Silvio

“…The risk of coronavirus disease-19 infection for healthcare professionals and patients in hospitals remains unclear. We investigated whether precautions…”
Get full text

The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease by Bonifacio, Cristiana, Savini, Giovanni, Reca, Christian, Garoli, Federico, Levi, Riccardo, Vatteroni, Giulia, Balzarini, Luca, Allocca, Mariangela, Furfaro, Federica, Dal Buono, Arianna, Armuzzi, Alessandro, Danese, Silvio, Matteoli, Michela, Rescigno, Maria, Fiorino, Gionata, Politi, Letterio S.

“…The dysregulation of the gut-brain axis in chronic inflammatory bowel diseases can cause neuro-psychological disturbances, but the underlying mechanisms are…”
Get full text

The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease by Avila-Ribeiro, Pedro, Fiorino, Gionata, Danese, Silvio

“…biosimilars are similar versions of existing innovator biologic agents but with distinct manufacturing processes. They were approved in inflammatory bowel…”
Get more information

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar‐treated IBD patients by Pouillon, Lieven, Danese, Silvio, Hart, Ailsa, Fiorino, Gionata, Argollo, Marjorie, Selmi, Carlo, Carlo‐Stella, Carmelo, Loeuille, Damien, Costanzo, Antonio, Lopez, Anthony, Vegni, Elena, Radice, Simona, Gilardi, Daniela, Socha, Marie, Fazio, Maria, González‐Lorenzo, Marien, Bonovas, Stefanos, Magro, Fernando, Peyrin‐Biroulet, Laurent

“…Summary Background The nocebo effect is a negative effect of a pharmacological or nonpharmacological medical treatment that is induced by patients'…”
Get full text

Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO] by Sigall-Boneh, Rotem, Levine, Arie, Lomer, Miranda, Wierdsma, Nicolette, Allan, Philip, Fiorino, Gionata, Gatti, Simona, Jonkers, Daisy, Kierkus, Jaroslaw, Katsanos, Konstantinos H, Melgar, Silvia, Yuksel, Elif Saritas, Whelan, Kevin, Wine, Eytan, Gerasimidis, Konstantinos

“…Although the current doctrine of IBD pathogenesis proposes an interaction between environmental factors and gut microbiota in genetically susceptible…”
Get full text

Proactive TDM for Crohn’s Disease Patients in Clinical Remission Under Anti-TNF Treatment: Current State of Evidence by Torres, Joana, Bonovas, Stefanos, Fiorino, Gionata

Get full text

MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice by Ungaro, Federica, Tacconi, Carlotta, Massimino, Luca, Corsetto, Paola Antonia, Correale, Carmen, Fonteyne, Philippe, Piontini, Andrea, Garzarelli, Valeria, Calcaterra, Francesca, Della Bella, Silvia, Spinelli, Antonino, Carvello, Michele, Rizzo, Angela Maria, Vetrano, Stefania, Petti, Luciana, Fiorino, Gionata, Furfaro, Federica, Mavilio, Domenico, Maddipati, Krishna Rao, Malesci, Alberto, Peyrin-Biroulet, Laurent, D’Alessio, Silvia, Danese, Silvio

“…Alterations in signaling pathways that regulate resolution of inflammation (resolving pathways) contribute to pathogenesis of ulcerative colitis (UC). The…”
Get full text

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? by Peyrin-Biroulet, Laurent, Fiorino, Gionata, Buisson, Anthony, Danese, Silvio

“…Therapy for Crohn's disease has traditionally been based on a step-up approach, with treatment with the powerful TNF antagonists reserved as a last resort…”
Get full text

Adalimumab and Azathioprine Combination Therapy for Crohn’s Disease: A Shining Diamond? by Fiorino, Gionata, Danese, Silvio

Get full text

The biosimilar road in inflammatory bowel disease: The right way? by Fiorino, Gionata, MD, PhD, Danese, Silvio, MD, PhD

“…Abstract The biologicals have led to dramatic changes in the management of immune-mediated diseases, and the subsequent development of their biosimilars may…”
Get full text